Introduction
============

*RhoE*, also known as rho family GTPase (Rnd) 3 (*Rnd3*) or small GTP-binding protein *Rho8*, encodes a protein that belongs to a member of the small GTPase protein super-family ([@b1-ijmm-46-03-1225]). Unlike the traditional Rnd family of proteins, RhoE cannot switch from the GTP-bound to GDP-bound forms to mediate its activity ([@b1-ijmm-46-03-1225]). Since it was first identified in 1996, many physiological and pathophysiological functions of RhoE have been uncovered ([@b2-ijmm-46-03-1225]-[@b5-ijmm-46-03-1225]). Early studies suggested that RhoE was associated with RhoA/Rho-associated coiled-coil kinase signaling in regulating actin cytoskeleton organization ([@b6-ijmm-46-03-1225],[@b7-ijmm-46-03-1225]). Studies performed over the past decade using *RhoE* gene-edited cells and animal models have revealed additional RhoE functions ([@b8-ijmm-46-03-1225]-[@b12-ijmm-46-03-1225]), which highlighted the complex role of RhoE in mammalian diseases. A more comprehensive understanding of the function and interactions mediated by RhoE, in addition to the signaling pathways associated with this protein, may provide novel insights into the role of RhoE in human health and diseases.

Cardiovascular disease presents a significant threat to human health. RhoE has been previously reported to promote endothelial barrier recovery during inflammatory challenge ([@b13-ijmm-46-03-1225]) and alleviate vascular injury caused by insulin resistance ([@b14-ijmm-46-03-1225]). The successful establishment of *RhoE*-knockout and *RhoE*-overexpressing mouse models has allowed the discovery of the relationship between RhoE and cardiovascular diseases. Yue *et al* ([@b15-ijmm-46-03-1225]) previously generated the RhoE^+/−^ haploinsufficient mouse model, which is predisposed to transverse aortic constriction stress and develop apoptotic cardiomyopathy with heart failure. Additionally, the same research group also found impaired angiogenesis in this animal model through destabilization of the hypoxia inducible factor 1α-vascular endothelial growth factor-A signaling pathway ([@b8-ijmm-46-03-1225]). Subsequently, it was revealed further that *RhoE*-null mice were embryonically lethal with cardiac arrhythmias due to the aberrant activation of the β-adrenergic receptor-protein kinase A signaling pathway ([@b10-ijmm-46-03-1225]). By applying global *RhoE*-knockout, cardiomyocyte-specific *RhoE* heterozygous and cardiomyocyte-specific *RhoE* overexpressing mice, it was found recently that RhoE regulated myocardial infarction-induced inflammation and promoted cardiac recovery from injury by mediating NF-κB signaling ([@b12-ijmm-46-03-1225]). Taken together, these results aforementioned suggest that the targeted manipulation of *RhoE* can be a potential method of therapeutic intervention for major cardiovascular diseases.

To elucidate the role of RhoE in cardiovascular diseases, a *RhoE*-knockout H9C2 cardiomyocyte cell line was produced using CRISPR/Cas9 technology. Whole genome expression gene chip technology was then used to detect differentially expressed genes (DEGs) between the *RhoE*-knockout and wild-type H9C2 cell models. By performing ingenuity pathway analysis (IPA) using the IPA software (version 42012434; Ingenuity Systems; Qiagen China Co., Ltd.), the global profiles of signaling pathways, functions and interactions associated with *RhoE* were obtained. Data obtained from the present study provide a general overview of the role and targeted intervention of RhoE during pathological conditions in the cardiovascular system.

Materials and methods
=====================

Cell culture
------------

H9C2 cardiomyocytes and 293T cells were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. The cells were maintained in DMEM (HyClone; GE Healthcare Life Sciences) supplemented with 10% FBS (Life Technologies; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 *µ*g/ml streptomycin at 37°C in a humidified atmosphere under 5% CO~2~. The medium was changed every 3 days. Cells were routinely tested for contamination with mycoplasma or chlamydia before being used in subsequent experiments.

RhoE-knockout in H9C2 cardiomyocytes using CRISPR/Cas9 technology
-----------------------------------------------------------------

Obtaining the RhoE^−/−^ mice was difficult due to high embryonic lethality after E11.5 ([@b2-ijmm-46-03-1225]). Therefore, CRISPR/Cas9 technology was used to edit the RhoE gene in H9C2 cardiomyocytes. The GV392 plasmid (also named LV-hspCas9-P2A-puro; Shanghai GeneChem Co., Ltd.) was used ([@b16-ijmm-46-03-1225]). Three single guide RNAs (sgRNAs) specific to rat *RhoE* and one scramble sgRNA were designed using the Cas-Designer online web tool (<http://www.rgenome.net/cas-designer/>) ([@b17-ijmm-46-03-1225]), where their associated oligonucleotide sequences were synthesized by Shanghai GeneChem Co., Ltd. The sequences of the sgRNA oligonucleotides are listed in [Table SI](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}. The oligonucleotides were then ligated into the linearized lentiviral vector GV392. Following verification of the plasmids by Sanger sequencing on the Shanghai GeneChem Co., Ltd. platform, lentiviral particles were produced in 293T cells by co-transfecting them with the plasmid Helper 1.0 and Helper 2.0 plasmids (Shanghai GeneChem Co., Ltd.) using Lipofectamine^®^ 3000 (Thermo Fisher Scientific, Inc.) for 48 h before collection. The masses of the LV-hspCas9-P2A-puro, Helper 1.0 and Helper 2.0 plasmids used were 20, 15 and 10 *µ*g per transfection reaction in 10-cm dishes. The physical structures of the plasmids and the sequences of the sgRNA are shown in [Fig. S1](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}. To identify the functionality of the sgRNA, H9C2 cells were infected with the lentiviral particles at multiplicity of infection of 100. At 48 h post-infection 2.0 *µ*g/ml puromycin was added to stress the cells continuously for 5 days. Genomic DNA was then extracted using the TIANamp Genomic DNA kit (Tiangen Biotech Co., Ltd.), which was subjected to semi-quantitative PCR analysis to measure *RhoE* expression. For the PCR analysis, 2X Taq Plus Master Mix (Vazyme Biotech Co., Ltd.) was used and thermocycling conditions were: Initial denaturation at 95°C for 90 sec, followed by 35 cycles of 95°C for 20 sec, 55°C for 20 sec and 72°C for 50 sec. Following a final cycle of 98°C for 3 min, the products were cooled at room temperature to below 40°C. Knockout and Mutation Detection kit (cat. no. MB001-100420rnx; Shanghai Genesci Medical technology Co., Ltd.) was used to verify RhoE-knockout in H9C2 cells. PCR products were treated with Detecase with the suitable buffer under 45°C for 20 min. Subsequently, the products were subjected to 2.0% agarose gel electrophoresis containing SyBR™ Green I Nucleic Acid Gel Stain solution (cat. no. S7563; Thermo Fisher Scientific, Inc.) and visualized using Tanon 4200 gel imaging system (version 1.0, Tanon Science and Technology Co., Ltd.). Since the cells in the RhoE-knockout group is of mixed clone, mutation of the same target site among the cells is different. After annealing, the PCR product can form a mismatch site and be recognized by the mismatch enzyme Detecase, which can detect the activity of sgRNA according to the cleaved bands. The PCR product of the *Cdc42* gene (Shanghai GeneChem Co., Ltd.) served as the positive control. The primers for PCR and respective product sizes before and after cruiser nuclease digestion are provided in [Table SII](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}. Finally, the functional lentiviral particles were used to infect H9C2 cardiomyocytes at multiplicity of infection of 100. Puromycin (2.0 *µ*g/ml) was added to stress the cells continuously for 7 days, before western blotting was performed to measure the RhoE protein expression and total RNA was subjected to whole genome expression profile chip analysis.

Microarray experiments using the GeneChem platform
--------------------------------------------------

The microarray experiments were performed by Shanghai GeneChem Co., Ltd. Briefly, total RNA was extracted from the cells using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to manufacturer\'s protocol, following which the quality was checked using the NanoDrop™ 2000 spectrophotometer (Life Technologies; ThermoFisher Scientific, Inc.) and Agilent Bioanalyzer 2100 (Agilent Technologies, Inc.). cDNA was then synthesized as per the protocols of the manufacturer using the GeneChip™ 3′ IVT Express kit (cat. no. 901228, Life Technologies; Thermo Fisher Scientific, Inc.), where the samples were incubated at 40°C for 16 h to produce biotin-labeled amplified RNA (aRNA). Rat whole genome expression chips (GeneChip^®^ Rat Genome 230 2.0 Array) were purchased from Affymetrix (cat. no. 900506; Life Technologies; Thermo Fisher Scientific, Inc.). This chip contains \>31,000 probe sets, can analyze \>30,000 transcripts and variants from \>28,000 well-substantiated rat genes. For each purified and fragmented aRNA sample, a hybridization cocktail was manually created using GeneChip™ Hybridization, Wash, and Stain kit (cat. no. 900720; Affymetrix; Life Technologies; Thermo Fisher Scientific, Inc.), which performed according to the protocols of the manufacturer. Subsequently, 130 *µ*l hybridization cocktail was added manually into the rat genome 230 2.0 array, which was hybridized for 16 h at 45°C. Following hybridization, the arrays were washed and stained on a GeneChip^®^ Fluidics Station 450 using reagents from the Hybridization, Wash, and Stain kit. Washed and stained arrays were subsequently scanned using a GeneChip^®^ Scanner 3000 (Life Technologies; Thermo Fisher Scientific, Inc.).

Data processing and IPA analysis
--------------------------------

The intensities of the hybridization signals were obtained using the GeneChip^®^ Scanner 3000 7G system (Life Technologies; Thermo Fisher Scientific, Inc.). The raw data obtained from the gene chips were normalized using the robust multichip average (RMA) algorithm ([@b18-ijmm-46-03-1225]) provided by \'Affy\' package of R language (version 1.46.1; <http://bioconductor.org/packages/release/bioc/html/affy.html>). DEGs were defined as fold change (FC) ≥1.2 in the corrected fluorescence values and P\<0.05 as assessed using unpaired-samples t-test. The IPA system (version 42012434, Ingenuity Systems; Qiagen China Co., Ltd.) was used for subsequent bioinformatics analysis, which included canonical pathway analysis, disease and function, regulator effects, upstream regulators and molecular networks. IPA uses a network generation algorithm to segment the network map between molecules into multiple networks and assign scores for each network ([@b19-ijmm-46-03-1225],[@b20-ijmm-46-03-1225]). The score is generated based on hypergeometric distribution, where the negative logarithm of the significance level is obtained by Fisher\'s exact test at the right tail. For canonical pathway analysis, disease and function, the −log (P-value) \>2 was taken as threshold, the Z-score \>2 was defined as the threshold of significant activation, whilst Z-score \<−2 was defined as the threshold of significant inhibition. For regulator effects and molecular networks, consistency scores were calculated, where a high consistency score indicates accurate results for the regulatory effects analysis. For upstream regulators, the P-value of overlap \<0.05 was set as the threshold. The algorithm used for calculating the Z-scores and P-values of overlap has been described previously ([@b21-ijmm-46-03-1225]).

Quantitative PCR (qPCR)
-----------------------

To verify the chip results, 20 genes of interest that were associated with the enriched canonical pathways were selected for qPCR analysis. cDNA was generated from 1.0 *µ*g RNA using a RevertAid First Strand cDNA Synthesis kit (cat. no. K1622; Thermo Fisher Scientific, Inc.). In total, 20 *µ*l reactive mixture and the SYBR^®^ Premix Ex Taq™ II kit (Takara Bio, Inc.) were used for the qPCR, as described previously ([@b22-ijmm-46-03-1225],[@b23-ijmm-46-03-1225]). The sequences of the primers are provided in [Table SIII](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}. The thermocycling conditions were as follows: Initial denaturation at 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec, 60°C for 10 sec and 72°C for 20 sec. The 2^−ΔΔCq^ method ([@b24-ijmm-46-03-1225]) was used to quantify the expression levels of target genes, with *GAPDH* as the internal control.

Western blotting
----------------

The procedure was performed as previously described ([@b23-ijmm-46-03-1225],[@b25-ijmm-46-03-1225]). In brief, cells were lysed with RIPA buffer (Beyotime Institute of Biotechnology), where the consequent protein samples were quantified using the bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). In total, 30 *µ*g proteins from each sample were subjected to 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. After washed and incubated with 5% skimmed milk in TBS-0.05% Tween-20 at 37°C for 2 h, membranes were probed with primary antibodies at 4°C overnight. After two washes with TBS-T, the membranes were incubated with horseradish peroxidase (HRP)-conjugated seconadry antibodies at 37°C for 1 h. The following antibodies were used: RhoE (1:200; cat. no. 66228-1-Ig; ProteinTech Group, Inc.), osteoprotegerin (TNFRSF11B; 1:500; cat. no. ab73400; Abcam), Casitas B-lineage lymphoma (CBL; 1:500; cat. no. ab119954; Abcam), structural maintenance of chromosomes 1A (SMC1A; 1:500; cat. no. ab133643; Abcam), cofilin-1 (CFL1; 1:500; cat. no. 5175; Cell Signaling Technology, Inc.), eukaryotic translation initiation factor 4e binding protein 1 (EIF4EBP1; 1:500; cat. no. 9644; Cell Signaling Technology, Inc.), SHC adaptor protein 1 (SHC1; 1:500; cat. no. 2432; Cell Signaling Technology, Inc.), cyclin D2 (CCND2; 1:1,000; cat. no. 3741; Cell Signaling Technology, Inc.), cyclin B1 (CCNB1; 1:1,000; cat. no. 4138; Cell Signaling Technology, Inc.), eukaryotic translation initiation factor 2 subunit (EIF2S; 1:500; cat. no. 5324; Cell Signaling Technology, Inc.), STAT3 (1:500, cat. no. 9139, Cell Signaling Technology, Inc.), GAPDH (1:1,000, cat. no. sc-32233, Santa Cruz Biotechnology, Inc.), horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (1:1,000, cat. no. sc-2004; Santa Cruz Biotechnology, Inc.) and HRP-anti-mouse IgG (1:1,000, cat. no. sc-2005; Santa Cruz Biotechnology, Inc.). Bands were visualized by using Pierce™ Fast Western Blot kit, ECL substrate (Thermo Fisher Scientific, Inc.) and analyzed with a Tanon 4200 gel analysis system (version 1.0, Tanon Science and Technology Co., Ltd.).

Statistical analysis
--------------------

The IPA system (version 42012434) was used to perform bioinformatics analysis. Pearson\'s correlation was used to compare the correlation of different groups of microarray hybridization signals. The right-tailed Fisher\'s exact test and unpaired t-test were used for analysis and validation of DEGs, P\<0.05 was considered to indicate a statistically significant difference. For the IPA analysis, the P-value, −log (P-value), P-value of overlap, Z-score and consistency scores were used, which were mentioned above. For producing of the heatmaps and analysis of qPCR results, GraphPad Prism (version 8.0, GraphPad Software, Inc.) was used.

Results
=======

Effective sgRNA designed against rat RhoE
-----------------------------------------

Three sgRNAs that target the rat *RhoE* DNA sequence were designed and packaged into lentiviruses using 293T cells. PCR was subsequently performed using the genome DNA samples derived from the virus-infected H9C2 cells. According to the cruiser enzyme digestion method, the heterologous double-stranded DNA with a mutation site can be efficiently cleaved from the 3 ′end of the mutation site by the nuclease, thereby generating fragments of different sizes. In the present study, after Cruiser digestion, the 838 bp product of NC-1 and KO-2 (sgRNA-2) could not generate any bands at 303 and 530 bp, whilst the 738 bp product of NC-2 and KO-3 (sgRNA-3) could not generate any bands at 247 and 491 bp. However, KO-1 (sgRNA-1) labeled, as indicated by the white asterisk, indicated that the lentivirus of interest had the correct sgRNA sequence, as it yielded a band at 303 and another at 530 bp after cruiser digestion ([Fig. 1A](#f1-ijmm-46-03-1225){ref-type="fig"}). This suggests that in conjunction with the Cas9 protein, sgRNA-1 functioned well in H9C2 cells, since it induced the correct mutation in the PCR products of the *RhoE* DNA exon sequence. In cells transfected with sgRNA-1, the western blotting results showed that RhoE protein expression was significantly suppressed, even in mixed clonal H9C2 cell pools consisting of cells with different RhoE DNA mutation efficiencies ([Fig. 1B](#f1-ijmm-46-03-1225){ref-type="fig"}), indicating a depletion of RhoE protein post editing. The heat maps representing *RhoE* mRNA expression in the control and knockout cells and the chip results further verified that the *RhoE* mRNA levels in the knockout group were significantly lower compared with those in cells transfected with scrambled sgRNA (NC; [Fig. 1C and D](#f1-ijmm-46-03-1225){ref-type="fig"}).

RhoE-knockout in H9C2 cells leads to significant changes in gene expression
---------------------------------------------------------------------------

Rigorous quality control of the RNA samples and chip data was conducted before the data were analyzed ([Figs. S2 and S3](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}). The *RhoE*-knockout H9C2 cells had a total of 829 DEGs compared with those in the wild-type control cells (FC ≥1.2 and P\<0.05), in which 417 were found to be upregulated and 412 were downregulated ([Fig. 2A and B](#f2-ijmm-46-03-1225){ref-type="fig"}). The top five upregulated genes were *LOC100912383*, *TNN*, *ClU*, *IL33* and *ATP7A*, whilst the top five downregulated genes were *WASl*, *HIST1H1D*, *IDI1*, *SCD1* and *TBL1X* ([Fig. 2B](#f2-ijmm-46-03-1225){ref-type="fig"}). The heat maps representing the top 20 upregulated and top 20 downregulated genes are shown in [Fig. 2C and D](#f2-ijmm-46-03-1225){ref-type="fig"}.

Enriched canonical pathways detected using IPA
----------------------------------------------

The complete list of enriched canonical pathways is included in [Table SIV](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}. A total of 67 enriched canonical pathways were identified by applying the −log (P-value) \>2 threshold, top 25 of the 67 representative pathways ranked according to their −log (P-value) that were found to associate tightly with the cardiovascular system are shown in [Fig. 3](#f3-ijmm-46-03-1225){ref-type="fig"}, along with the number of enriched genes that function within each of these signaling pathways. The \'superpathway of cholesterol biosynthesis\' was the highest ranking signaling pathway with a −log (P-value) of 17.5. Taking Z-score \>2 as the threshold of significant activation, it was subsequently found that \'androgen signaling\' (Z-score=2.236), \'interferon signaling\' (Z-score=2.236), \'nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated oxidative stress response\' (Z-score=2.236), \'Gβγ signaling\' (Z-score=2.236), \'oncostatin M signaling\' (Z-score=2.121) and \'thrombopoietin signaling\' (Z-score=2.121) were significantly activated ([Table SIV](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}). Although none of the detected signaling pathways had a Z-score \<−2, some of the enriched signaling pathways had Z-scores \<−1 ([Table SIV](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}), including the \'osteoarthritis pathway\' (Z-score=−1.508), \'Wnt/β-catenin signaling\' (Z-score=−1.414), \'TGF-β signaling\' (*Z*-score=−1.414), \'regulation of actin-based motility by Rho\' (*Z*-score=−1.414), \'NF-κB signaling\' (*Z*-score=−1.134), \'cell division cycle 42 (Cdc42) signaling\' (*Z*-score=−1.134), \'glioma invasiveness signaling\' and \'signaling by Rho family GTPases\' (*Z*-score=−1.069).

Upstream regulator analysis
---------------------------

Upstream regulators, including transcription factors, cytokines, small RNAs, receptors, kinases, chemical molecules and pharmacological agents can all regulate gene expression. By applying the P-value of overlap \<0.05 threshold, a total of 885 upstream regulators were enriched ([Table SV](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}). Among them, 59 had activation Z-scores \>2 and 60 had activation Z-scores \<−2. The top 15 activated and top 15 inhibited upstream regulators are listed in [Table I](#tI-ijmm-46-03-1225){ref-type="table"}. Cholesterol was found to be the most powerful activator (Z-score=4.423; P-value of overlap=5.86×10^−12^). In addition, the following 32 target molecules in the dataset were enriched: *ABCA7*, *ACSS2*, *BSG, CD14*, *CXCL2*, *CYP7A1*, *DHCR7, FADS1, FASN, FDFT1, FDPS, HMGCR, IDI1, INHBA, LDLR, LGALS3, MMP14, MSMO1, NSDHL, PMVK, PSAT1, RPL36AL, SC5D, SCD, SLC1A3, SLC7A5, SOCS3, SQLE, TIMP3, TM7SF2, UXT*, and *VCAM1*. Sterol regulatory element-binding protein cleavage-activating protein (SCAP) was revealed to be the most powerful inhibitor (Z-score=−4.617; P-value of overlap=2.12×10^−18^) with the following 22 target molecules in dataset also enriched: *ACSS2*, *CYP51A1*, *DHCR7*, *ELOVL6*, *FASN, FDFT1, FDPS, HMGCR, IDI1, INSIG1, LDLR, LSS, MSMO1, MVD, MVK, NSDHL, PMVK, SC5D, SCD, SQLE, TM7SF2*, and *TMEM97*.

Disease and function analysis
-----------------------------

By applying the −log (P-value) \>4 threshold on the IPA system, the role of RhoE in diseases and in cellular function was next determined. The complete disease and function classifications are provided in [Table SVI](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}. The top categories as ranked in accordance with their −log(P-value) are shown in [Fig. 4](#f4-ijmm-46-03-1225){ref-type="fig"}. A histogram containing some representative classifications of disease and function is shown in [Fig. 4A](#f4-ijmm-46-03-1225){ref-type="fig"} and the representative heatmap is shown in [Fig. 4B](#f4-ijmm-46-03-1225){ref-type="fig"}. *RhoE* was found to serve important roles in a number of diseases and cellular functions, including \'organismal survival\' \[−log (P-value)=23.567; Z-score=−2.362\], \'cancer, organismal injury and abnormalities\' \[−log (P-value)=12.551, Z-score=−3.03\], \'cell death and survival\' \[−Log (P-value)=4.577, Z-score=−2.068\], \'cell-to-cell signaling and interaction\' \[−log (P-value)=10.79, Z-score=2.54\], \'cellular function and maintenance\' \[−log (P-value)=6.807, Z-score=2.07\] and \'molecular transport\' \[−log (P-value)=4.137, Z-score=2.832\]. With the focus on cardiovascular disease and development function, *RhoE* was demonstrated to serve a role in 36 aspects, including \'disorder of blood pressure\' \[−log (P-value)=5.019, Z-score=−1.000\], \'hypertension\' \[−log (P-value)=4.724, Z-score=null\], \'cell death of cardiomyocytes\' \[−log (P-value)=4.119, Z-score=0.956\], \'abnormality of heart ventricle\' \[−log (P-value)=7.080, Z-score=0.923\], \'binding of endothelial cells\' \[−log (P-value)=5.678, Z-score=2.729\], \'adhesion of endothelial cells\' \[−log (P-value)=4.830, Z-score=2.444\], \'angiogenesis\' \[−log (P-value)=8.197, Z-score=−0.024\] and \'vasculogenesis\' \[−log (P-value)=7.381, Z-score=−0.604\] ([Fig. 4C and D](#f4-ijmm-46-03-1225){ref-type="fig"}).

Regulatory effects analysis
---------------------------

The regulatory effects analysis shows the possible pathways of upstream regulatory networks and downstream functions that involve the DEGs ([@b26-ijmm-46-03-1225]). Consistency score is an indicator used to describe the causal consistency of the upstream regulatory factor in the network, the dataset and dense connection metric between disease and function ([@b27-ijmm-46-03-1225]). In total, 33 types of regulatory effects were found ([Table SVII](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}). Among them, the highest ranked regulatory effect with a consistency score of 8.043 strongly suggests that the *RhoE*-knockout-induced DEGs *CD28, CHUK, IFNAR1, IKBKG, INSR*, and *RIPK2* may be involved in the adhesion of endothelial cells and recruitment of myeloid cells, mainly through mediating their targets, including *AXL, CXCL12, CXCL2, HSPA1A/HSPA1B, CYP1B1, IL33, IRF7, SERPINE1, SPP1, STAT1, STAT3, UCP2* and *VCAM1* ([Fig. 5](#f5-ijmm-46-03-1225){ref-type="fig"}).

Molecular network analysis
--------------------------

The interaction network analysis shows the interactions between molecules in the dataset. All networks were then sorted using the score values. The highest ranked network (score 52) was found to mainly affect \'neurological disease, hereditary disorder, organismal injury and abnormalities\', involving 35 molecules (*ACTR3*, *DNPEP, DPYSL3*, *DUS2*, *DYSF*, *ECH1, ENY2*, *EPDR1*, *EPRS*, *ERF*, *FAM136A*, *Flt1*, *HNRNPUL1*, *HPRT1*, *KARS*, *LEPROTL1*, *MAG*, *MAPK3*, *MARS*, *MRPS16*, *MYRF*, *NF2*, *PRPF40A*, *RBFOX2*, *RERE*, *Rho gdi*, *SCAND1*, *SDCBP*, *SERTAD2, TCEAL9*, *TNKS2, TPR*, *TSN*, *XPNPEP3*, and *ZBTB14*; [Table SVIII](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}). The associated interaction network map in terms of these aforementioned molecules is shown in [Fig. 6](#f6-ijmm-46-03-1225){ref-type="fig"}. The network ranked at no. 19 affects \'cardiovascular disease\' and \'cardiovascular system development and function\', which involves 35 molecules (*Arf*, *ARF3, Calcineurin A, CMIP, elastase, ELF2, Ephb, EPHB4, ETS, FKBP2, FKBP1A*, *HMMR, NCK, NR2F2, OAF, PABPN1, PAIP2, PAPOLA, Pde4, peptidylprolyl isomerase, Pmca*, *PMEPA1, PPIC, PURB*, *RNF111, Smad, SMAD6, Smad1/5/8*, *Smad2/3-Smad4*, *Smad2/3, TCF23, TGFBR, TM2D3, Vegf*, and *Wasl*; [Table SVIII](#SD1-ijmm-46-03-1225){ref-type="supplementary-material"}).

Validation of target genes
--------------------------

In total, 20 of the genes of interest were selected for qPCR validation and 10 protein products were verified by western blotting. These genes were chosen from the list of enriched canonical pathways, a proportion of which were found to be the DEGs. Since H9C2 cells with *RhoE*-knockout proliferate slowly (data not shown), genes associated with cell cycle were also subjected to validation. The expression levels of the genes that were found to be upregulated after *RhoE*-knockout (*ELK1*, *FTH1*, *ADAM10*, and *TNFRSF11b*) and the genes that were downregulated (*TIMP3*, *IL6st*, *SMC1a*, *CCNB1*, *CCND2*, *CCNA1*, *SHC1*, *CCXL12*, *JAK2*, *CDK6*, *CBL*, and *DUSP1*; [Fig. 7](#f7-ijmm-46-03-1225){ref-type="fig"}).

Discussion
==========

To investigate the global gene profile affected by alterations in *RhoE* expression, *RhoE*-knockout and wild-type H9C2 cardiomyocytes were used as models to detect DEGs and identify the potential associated underlying signaling pathways. Achieving *RhoE*-knockout in H9C2 cells was a critical step, since obtaining *RhoE*-knockout cardiomyocytes *in vivo* is difficult because of the low efficiency (\<0.9%) in establishing adult RhoE^−/−^ mice due to the high embryonic lethality after *RhoE*-knockout ([@b10-ijmm-46-03-1225]). Therefore, the powerful genome editing system CRISPR/Cas9 was applied to establish RhoE-knockout in H9C2 cells ([@b28-ijmm-46-03-1225],[@b29-ijmm-46-03-1225]), which was ultimately successful. However, establishing a monoclonal H9C2 *RhoE*-knockout cell line was not possible due to the slow proliferative characteristics of the cells. Therefore, puromycin-stressed H9C2 cells of mixed clones was used to test the genome editing efficiency. Cells from the puromycin-stressed cell pools display heterogeneous genotypes in the mixed cell clones, thus, the mixed cell clones were not available for DNA sequencing. However, western blotting results confirmed that expression of the RhoE protein was significantly reduced after RhoE gene editing. Therefore, lentiviruses encoding the sgRNA-1 sequence and Cas9 were used for subsequent experiments.

After CRISPR/Cas9-mediated RhoE-knockout, potential DEGs were detected in the RhoE-knockout and wild-type H9C2 cells. The cells were first infected with the lentiviruses containing sgRNA-1 and Cas9 at a high multiplicity of infection of 100. Total RNA was then extracted and subjected to chip analysis. A total of 829 differential expressing genes were found, where 417 were upregulated and 412 were downregulated. The top five upregulated genes were *LOC100912383, TNN, CLU, IL33* and *ATP7A*, whilst the top five downregulated genes were *WAS1, HIST1H1D, IDI1, SCD1* and *TBL1X*. *LOC100912383* is an unannotated rat gene that encodes a protein with unknown function. The other nine genes are known protein-encoding genes with Gene ontology (<http://geneontology.org/>) and GeneCards (<https://www.genecards.org/>) annotations revealing associated functions, related pathways and associated diseases. Interestingly, a PubMed search indicated that the majority of the top five up- and downregulated genes were associated with cardiovascular system diseases ([@b30-ijmm-46-03-1225]-[@b34-ijmm-46-03-1225]). The DEGs found in the present study will facilitate the discovery of the global properties of *RhoE* further.

The IPA system can be applied to integrate gene expression, microRNA and small-scale experimental data ([@b20-ijmm-46-03-1225],[@b21-ijmm-46-03-1225]). It establishes a visualized experimental system that reveals the properties of molecules, including genes, proteins, chemicals and drugs, along with the network of interactions between these molecules. The present study applied the IPA system to uncover the signaling pathways, interactions and functional roles of DEGs associated with *RhoE*-knockout. The module of the canonical pathway analysis related to disease and function, regulator effects, upstream regulators and molecular networks was focused upon.

The results of canonical pathway analysis indicated that RhoE may be involved in 67 canonical pathways with \'cholesterol biosynthesis\' superpathway found to be the highest ranking signaling pathway, suggesting the potential role of RhoE in cholesterol biosynthesis. In addition, \'androgen signaling\', \'interferon signaling\', \'Nrf2-mediated oxidative stress response\', \'Gβγ signaling\', \'oncostatin M signaling\' and \'thrombopoietin signaling\' were also revealed to be significantly activated. In total, 40 signaling pathways yielded Z-scores ≥1 but none \>2. The \'osteoarthritis pathway\', \'Wnt/β-catenin signaling\', \'TGF-β signaling\', \'regulation of actin-based motility by Rho\', \'NF-κB signaling\', \'Cdc42 signaling\' and \'glioma invasiveness signaling\' and \'signaling by Rho family GTPases\' were found to be inhibited. Among the 67 enriched canonical pathways, \'NF-κB signaling\', \'oncostatin M signaling\', \'ERK/MAPK signaling\', \'leukocyte extravasation signaling\', \'IL-3 signaling\', \'GM-CSF signaling\', \'TGF-β signaling\', \'Interferon signaling\' and \'IL-22 signaling\' were associated with the inflammatory response. Subsequent PubMed search found three articles that reported a relationship between RhoE and NF-κB signaling ([@b12-ijmm-46-03-1225],[@b35-ijmm-46-03-1225],[@b36-ijmm-46-03-1225]), especially one recently published by Dai *et al* ([@b12-ijmm-46-03-1225]), which elegantly proved that RhoE deficiency led to the hyperactivation of NF-κB, resulting in the recruitment of inflammatory cells post myocardial infarction. Activation of NF-κB signaling serves a critical role in a number of human diseases, including that in the cardiovascular system ([@b37-ijmm-46-03-1225],[@b38-ijmm-46-03-1225]), the RhoE/NF-κB signaling axis is therefore a promising target for disease intervention. The large number of signaling pathways that were found to be enriched in the present study, which can potentially provide a resource for exploring human disease intervention strategies using RhoE as a molecular target.

Upstream regulator analysis detected 885 upstream regulators that were enriched. Cholesterol was identified as the most powerful activator whereas SCAP was the most powerful inhibitor. Rosuvastatin, atorvastatin, lovastatin and pitavastatin are drugs that have been widely used for the treatment of cardiovascular diseases ([@b39-ijmm-46-03-1225]). Interestingly, these four statins were found to be enriched and were potential inhibitors, all with Z-scores \<−2. The upstream regulators detected in the present study provide a reference for elucidating the mechanism of molecular disorders in specific diseases that are associated with aberrant *RhoE* expression.

The disease and functional analysis indicated further that RhoE has multifaceted functionality. Organismal survival was demonstrated to be in the top ranking category, which had annotations related to morbidity or mortality, with 241 associated molecules that were enriched. The absence of RhoE strongly predicted an impairment in this function, with a Z-score of −2.362. A previous report indicated that the long noncoding RNA TUG1 modulated the proliferation of trophoblast cells via the epigenetic suppression of RhoE, leading to the onset of pre-eclampsia ([@b40-ijmm-46-03-1225]), thereby highlighting the function of RhoE in organismal survival. There were numerous reports on the function of RhoE in cancer, organismal injury and abnormalities. For cancers of the digestive system ([@b41-ijmm-46-03-1225]-[@b43-ijmm-46-03-1225]), breast ([@b44-ijmm-46-03-1225]), prostate ([@b45-ijmm-46-03-1225]) and brain ([@b46-ijmm-46-03-1225]), RhoE has been previously identified as a tumor suppressor. However, RhoE has also been documented to serve as a tumor promoter in gastric and lung cancers ([@b47-ijmm-46-03-1225],[@b48-ijmm-46-03-1225]). The role of RhoE in cancer seems to be dependent on the cell type ([@b5-ijmm-46-03-1225]). In the present study, RhoE was also revealed to serves roles in a total of 36 aspects of cardiovascular disease and development function. Binding of endothelial cells and adhesion of endothelial cells are the two processes that were predicted to be strongly increased, whilst angiogenesis and vasculogenesis are predicted to be reduced even though the *Z*-scores were lower. Breslin *et al* ([@b13-ijmm-46-03-1225]) provided evidence that supports RhoE function in vascular endothelial barrier recovery and Yue *et al* ([@b8-ijmm-46-03-1225]) proposed that RhoE deficiency suppressed angiogenesis in heart failure. These aforementioned previous reports suggest that RhoE serves a role in cardiovascular diseases and has potential value for targeted interventions. Apart from cardiovascular diseases and function, RhoE may also regulate \'cell cycle\' progression, \'cell-to-cell signaling and interaction\', \'cellular function and maintenance\', and \'molecular transport\', which further demonstrate the versatility of RhoE.

A total of 33 kinds of regulatory effects were predicated using the IPA system. Adhesion of endothelial cells and recruitment of myeloid cells were thought to be the top effects after RhoE-knockout. Additionally, \~33% of the total regulatory effects were associated with cancer, followed by inflammation. Taken together, the DEGs established a total of 25 regulatory networks. The top network, ranked based on scores, mainly affects \'neurological disease, hereditary disorder, organismal injury and abnormalities\', involving 34 molecules. The regulatory effects and networks revealed the major interactions involving the differential molecules after *RhoE*-knockout.

In total, 20 genes were selected for qPCR validation and 10 proteins for western blotting validation, which found that some targets were upregulated and some were downregulated. These genes belong to a number different signaling pathways, including those in oncostatin M signaling, Nrf2-mediated oxidative response, Cholesterol signaling, Eph-Ephrin signaling, ATM signaling, EIF2 signaling, HMGB1 signaling and cell cycle progression. Of note, *CCNB1*, *CCNA1* and *CDK6* were found to be significantly inhibited, which may help explain the phenomenon that the H9C2 cells proliferated slowly after *RhoE*-knockout. *SCAP* (Cholesterol signaling), *IL6ST*, *TIMP3*, *JAK2 and* SHC1 (oncostatin M signaling) were downregulated. *FTH1* (Nrf2-mediated oxidative response), *ABAM10* (Eph-Ephrin signaling) and TNFRSF11B (HMGB1 signaling) and were upregulated. Surprisingly, *Elk1*, which serves the oncostatin M signaling pathway, was found to be upregulated, which was not consistent with the Chip data. Therefore, the bias of the experimental system is a limitation that needs to be considered. There are a number limitations associated with the present study: (i) Specific animal models should be established to verify these *in vitro* results; (ii) According to the IPA analysis, further research is needed to focus on the mechanisms involving the differential signaling pathways and molecular networks that are specific to cardiovascular diseases; (iii) Due to the inherent defects of CRISPR/Cas9 technology, the potential off-targets effects of sgRNA cannot be completely ruled out at present, meaning that other genome editing methods can be used to verify the results of this study.

In conclusion, the present study knocked out the *RhoE* gene in H9C2 cells using CRISPR/Cas9 technology, which obtained the *RhoE*-knockout cells. Subsequently, a set of DEGs between *RhoE*-knockout and wild-type H9C2 cells was obtained using genome-wide expression microarrays. Using the microarray data, the potential canonical signaling pathways and the associated diseases and function, upstream regulatory molecules, regulatory effects and interaction networks involving the DEGs as a result of *RhoE*-knockout were enriched and analyzed using the IPA system. RhoE was speculated to regulate a multitude of pathways, including the superpathway of cholesterol biosynthesis, oncostatin M signaling, interferon signaling and regulation of actin-based motility by Rho. In addition, data from the present study also suggest that RhoE serves a role in diseases and functions, including organismal survival, cancer, cardiovascular disease and development function. The present study uncovered some of the previously unknown global biological and functional properties of RhoE.
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![Knockout of RhoE expression in H9C2 cells using CRISPR/Cas9 technology. (A) Representative images of the DNA gels from H9C2 cells showing the fragments of PCR products. PC represents the *Cdc42* gene positive control, which was proven to be correctly recognized by Detecase, with the product at 456 bp and the fragments at 151 and 303 bp after Cruiser digestion. NC-1 represents cells infected with the scrambled sgRNA-overexpressing viruses, where primer pairs for sgRNA-1 were used; NC-2 represents cells infected with the scrambled sgRNA-overexpressing viruses, where primer pairs for sgRNA-3 were used. (B) Western blot analysis of RhoE protein expression in the mix clone population of H9C2 cells. (C) Heatmap representing the mRNA the expression levels of RhoE and the internal control GAPDH in H9C2 cells. (D) Chip results of RhoE mRNA expression in H9C2 cells from the knockout and NC groups. FC, fold change; KO, knockout; PC, positive control; NC, negative control.](IJMM-46-03-1225-g00){#f1-ijmm-46-03-1225}

![Differentially expressed genes in H9C2 cells after *RhoE*-knockout. (A) Volcano plot. The x-axis represents log~2~ conversion of the fold change values, whilst the y-axis represents the corrected significance level after base log~10~ conversion. Red dots in the figure indicates all probes with significance levels \<0.05. (B) Scatter plot indicating the top five upregulated and downregulated genes. (C and D) Data from Chip assay were used to generate the maps using the GraphPad Prism 8.0 software. Heatmap of (C) the top 20 upregulated and (D) top 20 downregulated genes. Compared NC with KO, genes in red color were indicated to be up-regulated and genes in blue color were indicated to be downregulated. NC, negative control; KO, knockout.](IJMM-46-03-1225-g01){#f2-ijmm-46-03-1225}

![Histogram of the 25 canonical pathways. The left y-axis represent the -log (P-value) and the right y-axis represents the number of genes counted of each of the representative canonical pathways. IGF-1, insulin-like growth factor 1; AMPK, 5′AMP-activated protein kinase; JAK, janus kinase; IL, interleukin; LXR/RXR, liver X receptor/retinoid X receptor; GM-CSF, granulocyte macrophage-colony-stimulating factor; TGF-β, transforming growth factor-β.](IJMM-46-03-1225-g02){#f3-ijmm-46-03-1225}

![Classification of diseases and functions. (A, C and D) Categories are shown in terms of the -log (P-value), as represented by the left y-axis and the number of differentially expressed genes counted, represented by the right y-axis. (A) A total of 24 representative classification of diseases and functions possibly mediated by RhoE are plotted. (B) Heatmap representing the classification of diseases and functions. This heatmap was drafted according its Z-score values, where higher Z-scores represented by orange indicates activation, whilst lower Z-scores represented by blue indicates inhibition. (C) Classification of pathophysiological processes possibly mediated by RhoE in cardiovascular disease. (D) Classification of possible functions of RhoE in cardiovascular system development and function.](IJMM-46-03-1225-g03){#f4-ijmm-46-03-1225}

![Network diagram representing the regulatory effects with top consistency scores. After RhoE-knockout, the top network, which yielded a consistency score=8.043, was \'adhesion of endothelial cells, recruitment of myeloid cells\'. Possible regulatory pathways regulating the recruitment of myeloid cells and adhesion of endothelial cells are displayed.](IJMM-46-03-1225-g04){#f5-ijmm-46-03-1225}

![Gene interaction network map. This network consists of the top ranked network found associated with the role of RhoE in neurological disease, hereditary disorder and organismal injury and abnormalities.](IJMM-46-03-1225-g05){#f6-ijmm-46-03-1225}

![Validation of target genes. (A) mRNA expression of 20 representative targets was validated using reverse-transcription-quantitative PCR. ^\*^P\<0.05. (B) Expression levels of 10 selected proteins were validated by western blotting. Black arrows indicate proteins with the most notably changed expression after RhoE-knockout. TNFRSF11B, osteoprotegerin; CBL, Casitas B-lineage lymphoma; SMC1A, structural maintenance of chromosomes 1A; CFL-1, cofilin-1; EIF4EBP1, eukaryotic translation initiation factor 4e binding protein 1; SHC1, SHC adaptor protein 1; CCND2, cyclin D2; CCNB1, cyclin B1; EIF2S1, eukaryotic translation initiation factor 2 subunit 1; HMGB1, High mobility group box 1; ATM, Ataxia telangiectasia mutated; NC, negative control, cells transfected with scrambled sgRNA; KO, knockout.](IJMM-46-03-1225-g06){#f7-ijmm-46-03-1225}

###### 

A list of 30 representative upstream regulators of *RhoE*.

  Upstream regulator   Molecule type             Predicted activation state   Activation z-score   P-value of overlap   Target molecules in dataset
  -------------------- ------------------------- ---------------------------- -------------------- -------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SCAP                 Other                     Inhibited                    −4.617               2.12×10^−18^         ACSS2,CYP51A1,DHCR7,ELOVL6,FASN,FDFT1,FDPS, HMGCR,IDI1, INSIG1,LDLR,LSS,MSMO1,MVD,MVK, NSDHL,PMVK,SC5D,SCD, SQLE,TM7SF2,TMEM97-
  SREBF2               Transcription regulator   Inhibited                    −4.310               2.55×10^−18^         ACSS2,CDKN1A,CYP51A1,DHCR7,ELOVL6,FASN,FDFT1,FDPS, GTF2I,HMGCR,IDI1,INSIG1,IRS2,LDLR,LSS,MSMO1,MVD,MVK, NSDHL,PMVK,SC5D,SCD,SQLE,TM7SF2,TMEM97-
  SREBF1               Transcription regulator   Inhibited                    −4.126               9.01×10^−14^         ACSS2,CDKN1A,CYP51A1,CYP7A1,DHCR7,ELOVL6,FADS1,FASN, FDFT1,FDPS,HMGCR,HSPA1A/HSPA1B,IDI1,INSIG1,IRS2,LDLR,LGA LS3,LSS,MLYCD,MSMO1,MVD,MYOG,NSDHL,PIK3R3,PMVK,SC5D, SCD,Scd2,SERPINE1,SQLE,TM7SF2,TMEM97,TTN,UCP2-
  INSR                 Kinase                    Inhibited                    −3.634               1.77×10^−06^ CC      ND1,CCND2,CDKN1A,CFL1,COL6A3,COX4I1,CYP1B1,CYP51A1, DAG1,DDR2,DHCR7,DUSP1,ETFB,FDFT1,FDPS,Foxn3,HMGCR,IDI1, LSS,MMP11,MSMO1,MVD,MVK,MXI1,NSDHL,OGDH,PDCD4,PDK4, SC5D,SERPINE1,SOCS3,SQLE,UCP2,VCAM1-
  Mibolerone           Chemical drug             Inhibited                    −3.313               1.95×10^−06^ CC      ND1,CCNL2,CLU,COL6A3,CYP4V2,CYP51A1,EIF2S1,FDPS, FKBP1A,IRF7,LDLR,LSS,Rrbp1,Scd2,SQLE,TGFBI,TIMP3,UCP2-
  Isoquercitrin        Chemical drug             Inhibited                    −3.302               1.48×10^−13^         CYP51A1,DHCR7,FASN,FDFT1,FDPS,HMGCR,INSIG1,LDLR,MSMO1, SC5D,SQLE
  Rosuvastatin         Chemical drug             Inhibited                    −3.302               5.42×10^−09^         CYP51A1,CYP7A1,DHCR7,FDFT1,FDPS,HMGCR,IDI1,LDLR,MVD, MVK,PMVK
  SIRT2                Transcription regulator   Inhibited                    −3.162               2.4×10^−10^          DHCR7,FDFT1,HMGCR,IDI1,LSS,MVD,MVK,PMVK,SC5D,SQLE
  Ezetimibe            Chemical drug             Inhibited                    −3.145               1.17×10^−10^         CYP51A1,DHCR7,FDFT1,FDPS,HMGCR,IDI1,LDLR,MVD,MVK, PMVK
  Atorvastatin         Chemical drug             Inhibited                    −3.002               2.17×10^−08^         ABCC1,CYP51A1,CYP7A1,CYR61,DHCR7,DUSP1,FDFT1,FDPS, HMGCR,HSD17B7,HYPK,IDI1,LDLR,LSS,MAPK3,MSMO1,MVD, MVK,NSDHL,PMVK,SERPINE1,SOD3,SPP1,SQLE,TM7SF2,VCAM1
  Lovastatin           Chemical drug             Inhibited                    −2.942               3.84×10^−07^         ADAM10,CCND1,CDKN1A,COTL1,DHCR7,EBNA1BP2,FASN,FDFT1, FDPS,HMGCR,LDLR,MPP6,MVD,MVK,PIK3R3,PMVK,SERPINE1, TNFRSF11B
  ATP7B                Transporter               Inhibited                    −2.887               7.03×10^−09^         CYP51A1,CYP7A1,ELOVL6,FASN,FDFT1,FDPS,HMGCR,IDI1,LDLR, LSS,MSMO1,SQLE
  Itavastatin          Chemical drug             Inhibited                    −2.800               5.59×10^−07^         CYP51A1,FDFT1,FDPS,HMGCR,IDI1,LSS,MVD,SQLE
  Pirinixic acid       Chemical toxicant         Inhibited                    −2.661               3.37×10^−11^         ABCC1,ACSS2,AKR1C3,ASNS,BSG,CCNB1,CCND1,CCT6A,CDKN1A, CFH,CLU,CXCL12,CYP7A1,ECH1,EIF3E,ELOVL6,FADS1,FASN, FKBP1A,Gk,GSTM3,HMGCR,Hmgn2 (includes others),ID2,IFITM3, INSIG1,LDLR,LGALS3,MARK2,MLYCD,NBN,PDCD4,PDK4,PIK3R3, PLA2G2A,PPIC,PSMB4,RBFOX2,RORA,RTN4,SC5D,SCD,SERPINE1, UBQLN2,UCP2,VCAM1,Yap1
  PPARGC1B             Transcription regulator   Inhibited                    −2.614               5.72×10^−07^         CCND1,COX4I1,FASN,FDFT1,FDPS,HMGCR,LSS,MVD,MVK,PDK4, SCD,SQLE
  Decitabine           Chemical drug             Activated                    2.724                1.57×10^−06^         ABCC1,AGRN,AKAP12,BCL2L11,BTG1,CCND1,CCND2,CD44, CDKN1A,CLU,COL6A3,CXCL12,CYP1B1,DUSP1,EPHB4,GSN,HMMR, HPRT1,HSPA1A/HSPA1B,IRF7,ISG15,ITGA3,JAG1,KLF6,KRT7,LDLR, LGALS3,MMP14,PXDN,SGK1,SHC1,SMARCA2,SOCS3,SPP1,STAT1, TFAP2A,TGFB2,TGFBI,TIMP3,Tpm3,UBA1
  IFNAR1               Transmembrane receptor    Activated                    2.760                2.02×10^−02^         AXL,CXCL2,HMGCR,IDI1,IRF7,ISG15,SDC1,SOCS3,SQLE,STAT1
  INSIG2               Other                     Activated                    2.764                1.41×10^−08^         ELOVL6,FASN,FDFT1,FDPS,HMGCR,INSIG1,LDLR,SCD
  RIPK2                Kinase                    Activated                    2.764                3.60×10^−03^         CXCL2,CYP7A1,FASN,HMGCR,IL33,LDLR,SCD,VCAM1
  SKIL                 Transcription regulator   Activated                    2.779                2.23×10^−05^         CDKN1A,COL4A1,CXCL12,DIXDC1,MYOG,SERPINE1,SLC44A1, Tpm3,ZEB1
  LMNB1                Other                     Activated                    2.804                2.07×10^−09^         CXCL12,CYP51A1,DHCR7,FASN,FSTL1,HMGCR,LDLR,MSMO1, PRRX2,SCD,SQLE,TGFB2,TGFBI,WISP2
  PEX5L                Ion channel               Activated                    2.970                6.14×10^−11^         CYP7A1,DHCR7,FDFT1,FDPS,HMGCR,IDI1,LSS,MVK,PMVK
  Poly rI: rC - RNA    Biologic drug             Activated                    2.994                4.49×10^−02^         ADAM10,ADAR,AGRN,AXL,CD14,CD44,CD47,CXCL2,DUSP1, ETNK1,IFITM3,IRF7,ISG15,JAK2,KLF6,PRKAR1B,RC3H2,STAT1, TIPARP,TNFRSF11B,TRAF6,TRIM25,VCAM1
  IFNG                 Cytokine                  Activated                    3.098                1.58×10^−05^ CC      AGRN,ARNT2,ASNS,ATG3,ATP1B1,ATP2A2,BCL2L11,BTG1,C1R, ND1,CCND2,CD14,CD44,CDKN1A,CIRBP,CXADR,CXCL12, CXCL2,DDR2,DRG1,DUSP1,ECE1,ELK1,ETS2,FASN,FHL2,FTH1, GAS6,GJA5,HMGCR,HSPA1A/HSPA1B,IDI1,IFITM3,INHBA,IRF7, IRS2,ISG15,ITGA6,ITGB1,JAG1,JAK2,KARS,KLF6,LAMC2,LGALS3, MMP11,MTSS1,MYOG,NDRG4,PAM,PHGDH,PLA2G2A,PRKCA, RAB12,SBNO2,SDC1,SERPINE1,SLC12A2,SLC1A3,SLC4A2,SLC7A5, SMTN,SOCS3,SOD3,SPP1,SQLE,STAT1,STAT3,STAT6,TBC1D10A, TGFB2,TIMP3,TNFRSF11B,TRAF6,UNC5B,VCAM1,ZYX
  IKBKG                Kinase                    Activated                    3.240                5.90×10^−03^         ATP2A2,CLU,CXCL12,CXCL2,IRF7,ISG15,NID1,SERPINE2,SGK1, SOCS3,SOD3
  CD28                 Transmembrane receptor    Activated                    3.320                1.40×10^−02^         ACTR3,AP1B1,BTG1,CBL,CBLB,CCND1,CCND2,CXCL2,FDPS, FKBP2,HAT1,HSPA1A/HSPA1B,IGFBP5,PSMF1,RAD23B,RORA, SLC7A5,SOCS3,STAT3,STEAP2,STRN3
  MAPK14               Kinase                    Activated                    3.376                7.84×10^−04^         CCNB1,CCND1,CYP51A1,CYP7A1,DUSP1,FASN,FDPS,HMGCR, LDLR,MYOG,SGK1,SHC1,SLC18A3,SOCS3,TNN,Tpm3
  INSIG1               Other                     Activated                    3.627                1.04×10^−11^         ACSS2,CXCL2,CYP51A1,DHCR7,ELOVL6,FADS1,FASN,FDFT1,FDPS, HMGCR,IDI1,IRS2,LDLR,LSS,MVK,PMVK,SCD,Scd2,SQLE,STEAP2, TM7SF2,UCP2
  POR                  Enzyme                    Activated                    3.754                3.97×10^−13^         ASNS,ATF5,C11orf54,CYP39A1,CYP51A1,CYP7A1,DHCR7,ELOVL6, FDFT1,FDPS,HMGCR,HSD17B12,IDI1,INSIG1,LDLR,LSS,MSMO1, MVD,MVK,NSDHL,PDK4,PGD,PMVK,SC5D,SCD,Scd2,SERPINA3, SQLE,STAT1,TM7SF2,TMEM97
  Cholesterol          Chemical- endogenous      Activated                    4.423                5.86×10^−12^         ABCA7,ACSS2,BSG,CD14,CXCL2,CYP7A1,DHCR7,FADS1,FASN, FDFT1,FDPS,HMGCR,IDI1,INHBA,LDLR,LGALS3,MMP14,MSMO1, NSDHL,PMVK,PSAT1,RPL36AL,SC5D,SCD,SLC1A3,SLC7A5,SOCS3, SQLE,TIMP3,TM7SF2,UXT,VCAM1
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